



ularly since the results of the study by Geser et al. suggest that malarial prophylaxis with chloroquine diminished the incidence of Burkitt lymphomas in Tanzania (2). In this regard, antioxidants, which have also been implicated in blocking autophagy, also prevent tumor formation in transgenic mice and xenograft models (16, 20). With chloroquine, this antimicrobial agent was initially thought to diminish lymphomagenesis by inhibiting malaria, but in fact its ability to inhibit autophagy through blocking lysosomal-mediated degradation as demonstrated by the current study by Maclean et al. appears to underpin its antitumorigenic activity in the clinical epidemiological setting (4). These instructive, insightful observations suggest that the use of chloroquine or its improved versions may prove to have a major impact in cancer prevention. It is notable, however, that the long-term effects of prolonged use of a potent autophagy inhibitor may have unexpected side effects, as our understanding of the homeostatic role of autophagy in normal tissues is rudimentary.

#### Acknowledgments

I apologize for omission of primary references and have largely relied on review

articles for this commentary. I thank J. Cleveland, P. Gao, M. Kastan, J. Kim, and J. Yustein for their input.

Address correspondence to: Chi V. Dang, Johns Hopkins University School of Medicine, Ross Research Building, Room 1032, 720 Rutland Avenue, Baltimore, Maryland 21205, USA. Phone: (410) 955-2411; Fax: (410) 955-0185; E-mail: cvdang@jhmi.edu.

- van den Bosch, C.A. 2004. Is endemic Burkitt's lymphoma an alliance between three infections and a tumour promoter? *Lancet Oncol.* **5**:738-746.
- Geser, A., Brubaker, G., and Draper, C.C. 1989. Effect of a malaria suppression program on the incidence of African Burkitt's lymphoma. *Am. J. Epidemiol.* **129**:740-752.
- Dang, C.V., O'Donnell, K.A., Zeller, K.I., Nguyen, T., Osthus, R.C., and Li, F. 2006. The c-Myc target gene network. *Semin. Cancer Biol.* **16**:253-264.
- Maclean, K.H., Dorsey, F.C., Cleveland, J.L., and Kastan, M.B. 2008. Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. *J. Clin. Invest.* **118**:79-88.
- Amaravadi, R.K., et al. 2007. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. *J. Clin. Invest.* **117**:326-336.
- Lum, J.J., et al. 2005. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. *Cell.* **120**:237-248.
- Brahimi-Horn, M.C., Chiche, J., and Pouyssegur, J. 2007. Hypoxia signalling controls metabolic

- demand. *Curr. Opin. Cell Biol.* **19**:223-229.
- Semenza, G.L. 2007. Hypoxia-inducible factor 1 (HIF-1) pathway. *Sci. STKE.* **2007**:cm8.
- Zeller, K.I., et al. 2006. Global mapping of c-Myc binding sites and target gene networks in human B cells. *Proc. Natl. Acad. Sci. U. S. A.* **103**:17834-17839.
- Cleveland, J.L., and Sherr, C.J. 2004. Antagonism of Myc functions by Arf. *Cancer Cell.* **6**:309-311.
- Rubinsztein, D.C., Gestwicki, J.E., Murphy, L.O., and Klionsky, D.J. 2007. Potential therapeutic applications of autophagy. *Nat. Rev. Drug Discov.* **6**:304-312.
- Maiuri, M.C., Zalckvar, E., Kimchi, A., and Kroemer, G. 2007. Self-eating and self-killing: crosstalk between autophagy and apoptosis. *Nat. Rev. Mol. Cell Biol.* **8**:741-752.
- Jin, S., and White, E. 2007. Role of autophagy in cancer: management of metabolic stress. *Autophagy.* **3**:28-31.
- Tracy, K., et al. 2007. BNIP3 is an RB/E2F target gene required for hypoxia-induced autophagy. *Mol. Cell Biol.* **27**:6229-6242.
- Scherz-Shouval, R., et al. 2007. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. *EMBO J.* **26**:1749-1760.
- Scherz-Shouval, R., and Elazar, Z. 2007. ROS, mitochondria and the regulation of autophagy. *Trends Cell Biol.* **17**:422-427.
- Colell, A., et al. 2007. GAPDH and autophagy preserve survival after apoptotic cytochrome c release in the absence of caspase activation. *Cell.* **129**:983-997.
- Reef, S., et al. 2006. A short mitochondrial form of p19ARF induces autophagy and caspase-independent cell death. *Mol. Cell.* **22**:463-475.
- Kamada, Y., et al. 2000. Tor-mediated induction of autophagy via an Apg1 protein kinase complex. *J. Cell Biol.* **150**:1507-1513.
- Gao, P., et al. 2007. HIF-dependent antitumorigenic effect of antioxidants in vivo. *Cancer Cell.* **12**:230-238.

## Hypertensive encephalopathy and the blood-brain barrier: is $\delta$ PKC a gatekeeper?

Wen-Hai Chou and Robert O. Messing

Ernest Gallo Clinic and Research Center, Department of Neurology, UCSF, Emeryville, California, USA.

**Hypertensive encephalopathy is a life-threatening condition due to elevation of cerebral perfusion pressure beyond the limits of autoregulation. Breakdown of the blood-brain barrier (BBB) leads to cerebral edema and reduced blood flow. In this issue of the JCI, Mochly-Rosen and colleagues demonstrate a novel molecular strategy for preserving the BBB in a model of hypertension-induced encephalopathy (see the related article beginning on page 173). Using a rationally designed peptide inhibitor of  $\delta$ PKC, they stabilized the BBB and improved mortality in hypertensive rats. This study highlights the therapeutic potential of  $\delta$ PKC inhibitors in hypertensive encephalopathy and provides incentive to elucidate  $\delta$ PKC signaling pathways that mediate BBB dysfunction in other disease states.**

**Nonstandard abbreviations used:** as-, analog sensitive; BBB, blood-brain barrier; RACK, receptor for activated c-kinase; TAT, transactivator of transcription; ZO-1, zonula occludens 1.


**Conflict of interest:** The authors have declared that no conflict of interest exists.

**Citation for this article:** *J. Clin. Invest.* **118**:17-20 (2008). doi:10.1172/JCI34516.

#### The blood-brain barrier

The blood-brain barrier (BBB) is a gliovascular unit composed of capillary endothelial cells and pericytes surrounded by basal lamina, astrocytic end-feet, and perivascular interneurons (Figure 1A) (1). The tight junctions formed between endothelial cells act as a highly effective

physical barrier to selectively permit the entry of required nutrients yet protect the central nervous system from pathogens and potentially harmful small molecules circulating in the blood. The tight junction consists of transmembrane proteins (claudin, occludin, and junction adhesion molecule) and cytoplasmic accessory proteins (Figure 1B) (2). Claudins form dimers and bind to claudins on adjacent endothelial cells to establish the primary gate of the tight junction. The main functions of occludin appear to be to regulate the electrical resistance across the barrier and decrease paracellular permeability. Several accessory cytoplasmic proteins associate with these transmembrane components. Zonula occludens proteins (ZO-1, ZO-2, and ZO-3) serve as recognition proteins for



**Figure 1**

Structure of the BBB and tight junction. **(A)** The BBB is formed in the central nervous system by capillary endothelial cells and surrounding perivascular elements (basal lamina, pericyte, astrocyte end-foot, and interneurons). **(B)** The tight junction is established by the interaction between the transmembrane proteins (claudins, occludin, and junction adhesion molecule) on adjacent endothelial cells. The C terminal of these transmembrane proteins is linked to cytoskeletal actin through ZO-1. In response to pathological stimuli,  $\delta$ PKC may directly or indirectly increase phosphorylation of ZO-1, thus disrupting the association between ZO-1 and the actin cytoskeleton. The disorganization of proteins at the tight junction may result in the aberrant permeability of the BBB.

tight junction placement and as support for signal transduction proteins. ZO-1 connects transmembrane proteins of the tight junction to the actin cytoskeleton. This interaction is critical for the stability and function of the tight junction because dissociation of ZO-1 from the cytoskeletal complex is frequently associated with increased barrier permeability (3). ZO-1 is phosphorylated by both serine/threonine and tyrosine kinases, which can, in turn, regulate ZO-1 localization and BBB function. Thus, activation of PKC by phorbol esters promotes the migration of ZO-1 to the plasma membrane and increases the permeability of the BBB (4).

Impairment of tight junctions leads to increased barrier permeability and occurs in a number of neurological disorders, including stroke, trauma, brain tumor, epilepsy, multiple sclerosis, Alzheimer disease, and hypertension (5). In hypertensive encephalopathy, BBB dysfunction is widespread and severe and produces


cerebral edema. The main goal of therapy is to reduce systolic blood pressure with drugs such as nitroprusside, adrenergic receptor blockers, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers to reduce levels of renin and angiotensin II produced in response to renal ischemia (6). However, there are no treatments that specifically target the disrupted BBB.

**$\delta$ PKC peptide inhibitor: TAT- $\delta$ V1-1**

The PKC family contains nine structurally related but functionally distinct serine/threonine kinases that transduce signals from lipid second messengers. The  $\delta$ PKC isozyme is expressed in several tissues and has been implicated in growth inhibition, cell death, and ischemic injury (7). Over a decade ago, D. Mochly-Rosen proposed a mechanism of PKC activation that involves the binding of an activated PKC isozyme to an isozyme-specific anchoring protein called a receptor for

activated *c*-kinase (RACK) (8). Based on this model, her laboratory has designed selective peptides to inhibit the binding of PKCs to their anchors and thereby inhibit PKC isozyme function. To allow these peptides to be delivered into cells, they can be conjugated with positively charged sequences, such as the HIV transactivator of transcription (TAT) protein-transduction domain (9).

In the paper by Mochly-Rosen et al. in this issue of the *JCI*, the authors report on their induction of hypertensive encephalopathy in Dahl salt-sensitive rats by feeding them a high-salt diet for 10 weeks beginning at 6 weeks of age (10). The hypertension disrupted BBB integrity, as demonstrated by increased BBB permeability and swelling of astrocytes and endothelial cells, and increased mortality, with 60% of salt-fed rats dying by the age of 15 weeks. The disorganization of tight junctions in these animals correlated with several biochemical changes, including reduced levels of

**Figure 2**

The chemical genetics approach. An as-kinase with a hole (in blue) recognizes the *N*6-(benzyl)-ATP- $\gamma$ S (BZ-ATP $\gamma$ S) with a bump and phosphorylates its unique substrates. Only the as-kinase, not wild-type kinases (in brown), can use *N*6-substituted ATP analogs (BZ-ATP $\gamma$ S) as phosphate donors. In the second step, alkylation with *p*-nitrobenzylmesylate (PNBM) forms thiophosphate esters and thioethers. Only esterified as-kinase substrates are recognized by specific antibodies discriminating thiophosphate esters from thioethers.

ZO-1 and occludin associated with the cytoskeleton, enhanced ZO-1 phosphorylation, and importantly, increased membrane translocation of  $\delta$ PKC (Figure 8 in ref. 9). Sustained administration of the selective  $\delta$ PKC inhibitor peptide TAT- $\delta$ V1-1 (11) beginning at week 11 attenuated phosphorylation of ZO-1, increased the association of ZO-1 and occludin with the actin cytoskeleton, reduced leakage at tight junctions, and improved the survival rate to greater than 90% at week 15. The beneficial effect of TAT- $\delta$ V1-1 was likely due to prevention of BBB breakdown, since treatment did not reduce the blood pressure or alter cardiac function. These results are quite striking, though a limitation to this study is that treatment was begun before the onset of encephalopathy. For practical therapeutic use, it will also be important in the future to determine whether the  $\delta$ PKC peptide inhibitor can reverse BBB breakdown after signs of encephalopathy appear.

The TAT- $\delta$ V1-1 peptide has been used successfully in several other experimental disease models, including cardiac ischemia and reperfusion (11–14), cerebral ischemia and reperfusion (15, 16), and chronic hypertension (10, 16). The peptide reduces infarct size in the heart (11–14) and brain (15, 16), possibly by attenuating apoptosis. The TAT- $\delta$ V1-1 peptide also increases blood flow and reduces microvascular pathology after cerebral ischemia and reperfusion (16).

$\delta$ PKC peptide inhibitors are attractive as therapeutics since they are rationally designed to be specific for the  $\delta$ PKC isozyme. Also, the peptides are water soluble, stable in solution, and easy to produce in large quantity. However, in general, the pharmacological properties of peptides are limited by short life due to proteolytic cleavage, uneven tissue distribution, and inadequate subcellular targeting. Although the effects of  $\delta$ PKC peptide inhibitors may provide useful information about the normal function of  $\delta$ PKC, the exact mechanism of action for TAT- $\delta$ V1-1 could be more complicated than originally anticipated (7). For example, activation of  $\delta$ PKC requires phosphorylation by Src tyrosine kinases and serine/threonine kinases. Binding of the activated kinase to its RACK is thought to target the kinase to its specific substrates. It is theoretically possible that TAT- $\delta$ V1-1 interference with  $\delta$ PKC-RACK binding may still allow  $\delta$ PKC to be active but at an unusual subcellular location, leading to phosphorylation of atypical substrates. Furthermore, in response to apoptotic stimuli, a constitutively active C terminal catalytic fragment of  $\delta$ PKC is cleaved from the N terminal domain responsible for binding to RACK and TAT- $\delta$ V1-1. The cleaved  $\delta$ PKC fragment appears to be essential for mediating apoptosis and is increased after transient cerebral ischemia (17). How TAT- $\delta$ V1-1 could interfere with the production or function of the  $\delta$ PKC

catalytic fragment is not clear. Therefore, although the beneficial effects of TAT- $\delta$ V1-1 suggest that  $\delta$ PKC serves a deleterious role under certain pathological conditions, it will be important to confirm such findings using additional methods such as genetic approaches to gain a clear understanding of the role of  $\delta$ PKC in disease.

### Molecular mechanisms of disease progression: identification of $\delta$ PKC substrates

The beneficial effects of TAT- $\delta$ V1-1 in models of ischemia and hypertension have increased interest in understanding the molecular and cellular actions of  $\delta$ PKC in disease progression. A detailed understanding of  $\delta$ PKC signaling pathways will ultimately require identification of  $\delta$ PKC substrates. Traditionally,  $\delta$ PKC substrates have been identified using pharmacological strategies with kinase activators or inhibitors, but lack of specificity of these modulators limits interpretation of these studies. However, recent work by Shokat and colleagues (18) has led to a novel chemical genetics approach to identifying immediate substrates of kinases. The approach targets the structurally conserved ATP-binding pocket within all kinases to generate mutant alleles that can utilize specific ATP analogs in addition to ATP. The mutation creates a “hole” by replacing a conserved bulky amino acid (e.g., valine or methionine) with a small residue



(alanine or glycine) in the ATP-binding pocket (Figure 2). A series of ATP analogs (benzyl-ATP) possessing a side group to fit into the engineered hole have been generated. Only the analog-sensitive (as-) mutant, not the wild-type kinase, can efficiently use these ATP analogs as phosphate donors. Therefore, only unique substrates of the as-kinase are labeled by the ATP analogs. A modification of this approach that generates a thiophosphate ester at the phosphorylation site for detection with an antibody has been successfully used to identify direct substrates of as-kinases (18). In our view, an as- $\delta$ PKC mutant will be an important tool for identifying specific  $\delta$ PKC substrates phosphorylated in response to ischemia and reperfusion, hypertension, and microvascular dysfunction. The  $\delta$ PKC signaling pathways revealed during disease progression should facilitate the development of additional  $\delta$ PKC-based therapeutic strategies.

#### Acknowledgments

This work was supported by NIH grant AA013588 and funds provided by the state of California for medical research on alcohol and substance abuse through the University of California at San Francisco (to

R.O. Messing) and by NIH grant NS057195 and UCSF REAC grant (to W.H. Chou).

Address correspondence to: Robert O. Messing, Ernest Gallo Clinic and Research Center at UCSF, 5858 Horton Street, Suite 200, Emeryville, California 94608, USA. Phone: (510) 985-3950; Fax: (510) 985-3101; E-mail: romes@gallo.ucsf.edu.

- Cecchelli, R., et al. 2007. Modelling of the blood-brain barrier in drug discovery and development. *Nat. Rev. Drug Discov.* **6**:650–661.
- Hawkins, B.T., and Davis, T.P. 2005. The blood-brain barrier/neurovascular unit in health and disease. *Pharmacol. Rev.* **57**:173–185.
- Mark, K.S., and Davis, T.P. 2002. Cerebral microvascular changes in permeability and tight junctions induced by hypoxia-reoxygenation. *Am. J. Physiol. Heart Circ. Physiol.* **282**:H1485–H1494.
- Harhaj, N.S., and Antonetti, D.A. 2004. Regulation of tight junctions and loss of barrier function in pathophysiology. *Int. J. Biochem. Cell. Biol.* **36**:1206–1237.
- Abbott, N.J., Ronnback, L., and Hansson, E. 2006. Astrocyte-endothelial interactions at the blood-brain barrier. *Nat. Rev. Neurosci.* **7**:41–53.
- Blumenfeld, J.D., et al. 2001. Renin system activation and delayed function of the renal transplant. *Am. J. Hypertens.* **14**:1270–1272.
- Steinberg, S.F. 2004. Distinctive activation mechanisms and functions for protein kinase Cdelta. *Biochem. J.* **384**:449–459.
- Mochly-Rosen, D. 1995. Localization of protein kinases by anchoring proteins: a theme in signal transduction. *Science*. **268**:247–251.
- Schwarze, S.R., Ho, A., Vocero-Akbani, A., and

Dowdy, S.F. 1999. In vivo protein transduction: delivery of a biologically active protein into the mouse. *Science*. **285**:1569–1572.

- Qi, X., Inagaki, K., Sobel, R.A., and Mochly-Rosen, D. 2008. Sustained pharmacological inhibition of  $\delta$ PKC protects against hypertensive encephalopathy through prevention of blood-brain barrier breakdown in rats. *J. Clin. Invest.* **118**:173–182.
- Chen, L., et al. 2001. Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC. *Proc. Natl. Acad. Sci. U. S. A.* **98**:11114–11119.
- Inagaki, K., et al. 2003. Inhibition of delta-protein kinase C protects against reperfusion injury of the ischemic heart in vivo. *Circulation*. **108**:2304–2307.
- Murriel, C.L., Churchill, E., Inagaki, K., Szewda, L.I., and Mochly-Rosen, D. 2004. Protein kinase Cdelta activation induces apoptosis in response to cardiac ischemia and reperfusion damage: a mechanism involving BAD and the mitochondria. *J. Biol. Chem.* **279**:47985–47991.
- Ikeno, F., Inagaki, K., Rezaee, M., and Mochly-Rosen, D. 2007. Impaired perfusion after myocardial infarction is due to reperfusion-induced deltaPKC-mediated myocardial damage. *Cardiovasc. Res.* **73**:699–709.
- Bright, R., et al. 2004. Protein kinase C delta mediates cerebral reperfusion injury in vivo. *J. Neurosci.* **24**:6880–6888.
- Bright, R., Steinberg, G.K., and Mochly-Rosen, D. 2007. DeltaPKC mediates microcerebrovascular dysfunction in acute ischemia and in chronic hypertensive stress in vivo. *Brain Res.* **1144**:146–155.
- Shimohata, T., et al. 2007. Suppression of deltaPKC activation after focal cerebral ischemia contributes to the protective effect of hypothermia. *J. Cereb. Blood Flow Metab.* **27**:1463–1475.
- Allen, J.J., et al. 2007. A semisynthetic epitope for kinase substrates. *Nat. Methods*. **4**:511–516.

## A skewed view of X chromosome inactivation

Jakub Minks, Wendy P. Robinson, and Carolyn J. Brown

Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.

**X chromosome inactivation involves a random choice to silence either X chromosome early in mammalian female development. Once silenced the inactive X is stably inherited through subsequent somatic cell divisions, and thus, females are generally mosaics, having a mixture of cells with one or the other parental X active. While in most females the number of cells with either X being active is roughly equal, skewing of X chromosome inactivation is observed in a percentage of women. In this issue of the JCI, Bolduc and colleagues address whether skewing of X chromosome inactivation in humans is influenced by an X-linked locus that can alter this initial random inactivation (see the related article beginning on page 333). Their data indicate that most of the skewing observed in humans results from secondary events rather than being due to an inherited tendency to inactivate a particular X chromosome.**

**Nonstandard abbreviations used:** *Xce*, X chromosome controlling element; XCI, X chromosome inactivation; *Xist*, X (inactive)-specific transcript.

**Conflict of interest:** The authors have declared that no conflict of interest exists.

**Citation for this article:** *J. Clin. Invest.* **118**:20–23 (2008). doi:10.1172/JCI34470.

#### What is skewed X chromosome inactivation?

X chromosome inactivation (XCI) — a process originally hypothesized by Lyon in 1961 (1) and by which one of the two copies of the X chromosome present in females is inactivated — achieves dosage

equivalency for X-linked genes between XY males and XX females. A critical tenet of this hypothesis was that the initial choice of which X (maternal or paternal) to inactivate was random but then this choice was stably inherited. An individual cell's decision to inactivate either the paternal or maternal X is made early in development, at approximately the time of implantation (2). A deviation from equal (50%) inactivation of each parental allele is known as skewing, with common criteria for “skewed” inactivation being arbitrarily defined as the observation of inactivation of the same allele in 75% or 80% of cells (and very skewed inactivation resulting in 90% or 95% of cells with the same allele inactive).

A solid understanding of the causes of skewed XCI is needed because skewing is often used as a tool in the clinical setting